LongeVC managing partner Sergey Jakimov and operating partner Artem Trotsyuk were featured in BioSpace, sharing their perspective on what it takes to build a credible longevity company in today's investment landscape.
In a discussion with Jennifer C. Smith-Parker, Sergey and Artem argued that the field's early stumbles were not due to weak science, but to an unfocused approach that treated aging as a vague, monolithic goal rather than a set of specific, measurable conditions. The path forward, they said, lies in targeting concrete disease indications with mechanistic clarity - and building evidence strategies that speak the language of regulators and payers from day one.
Read the full article here.
In a discussion with Jennifer C. Smith-Parker, Sergey and Artem argued that the field's early stumbles were not due to weak science, but to an unfocused approach that treated aging as a vague, monolithic goal rather than a set of specific, measurable conditions. The path forward, they said, lies in targeting concrete disease indications with mechanistic clarity - and building evidence strategies that speak the language of regulators and payers from day one.
Read the full article here.